Europe Foot and Ankle Allograft Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS 1 INTRODUCTION 32 1.1 OBJECTIVES OF THE STUDY 32 1.2 MARKET DEFINITION 32 1.3 OVERVIEW OF EUROPE FOOT AND ANKLE ALLOGRAFTS MARKET 32 1.4 LIMITATIONS 34 1.5 MARKETS COVERED 34 2 MARKET SEGMENTATION 37 2.1 MARKETS COVERED 37 2.2 GEOGRAPHICAL SCOPE 38 2.3 YEARS CONSIDERED FOR THE STUDY 39 2.4 CURRENCY AND PRICING 39 2.5 DBMR TRIPOD DATA VALIDATION MODEL 40 2.6 MULTIVARIATE MODELLING 43 2.7 END USER LIFELINE CURVE 43 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44 2.9 DBMR MARKET POSITION GRID 45 2.10 MARKET APPLICATION COVERAGE GRID 46 2.11 VENDOR SHARE ANALYSIS 47 2.12 SECONDARY SOURCES 48 2.13 ASSUMPTIONS 48 3 EXECUTIVE SUMMARY 49 4 PREMIUM INSIGHTS 51 4.1 PORTERS FIVE FORCES 52 5 INDUSTRIAL INSIGHTS: 53 5.1 CONCLUSION: 53 6 EUROPE FOOT AND ANKLE ALLOGRAFTS MARKET: REGULATIONS 54 6.1 U.S. 55 6.2 CANADA 56 6.3 EUROPE 56 7 MARKET OVERVIEW 58 7.1 DRIVERS 60 7.1.1 GROWING GERIATRIC POPULATION 60 7.1.2 INCREASE IN PREVALENCE OF MUSCULOSKELETAL DISORDER 60 7.1.3 INCREASE IN HEALTHCARE EXPENDITURE 61 7.1.4 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 62 7.2 RESTRAINTS 63 7.2.1 STRINGENT REGULATORY 63 7.2.2 COMPLICATION AND RISK OF ALLOGRAFTS 63 7.3 OPPORTUNITIES 64 7.3.1 INCREASE IN NUMBER OF SPORTS INJURIES 64 7.3.2 RISE IN AWARENESS INITIATIVES ABOUT THE ALLOGRAFT PROCEDURE: 65 7.3.3 INCREASING RISK OF OSTEOPOROSIS AND OSTEOARTHRITIS: 66 7.4 CHALLENGES 67 7.4.1 COVID-19 IMPACT ON EUROPE FOOT AND ANKLE ALLOGRAFTS MARKET 67 7.4.2 ALLOGRAFT IS OFTEN CONSIDERED TOO EXPENSIVE IN LOW-INCOME TO MIDDLE-INCOME COUNTRIES: 68 7.4.3 HIGHER ADOPTION OF ALTERNATIVE THERAPIES FOR THE TREATMENT OF FOOT AND ANKLE DISORDERS: 69 8 EUROPE FOOT AND ANKLE ALLOGRAFTS MARKET, BY PRODUCT TYPE 70 8.1 OVERVIEW 71 8.2 ALLOGRAFT WEDGES 74 8.3 ALLOGRAFT TENDONS 74 8.4 ALLOGRAFT ACELLULAR DERMAL MATRIX 75 8.5 CARTILAGE ALLOGRAFT MATRIX 76 8.6 SKIN ALLOGRAFTS 77 8.7 AMNIOTIC MEMBRANES 78 9 EUROPE FOOT AND ANKLE ALLOGRAFTS MARKET, BY SURGERY TYPE 79 9.1 OVERVIEW 80 9.2 ORTHOPEDIC RECONSTRUCTION 83 9.2.1 NON-UNIONS FRACTURES 84 9.2.2 ARTHRODESIS PROCEDURES 84 9.2.3 OSTEOTOMY PROCEDURES 84 9.3 CARTILAGE RESTORATION 84 9.3.1 TALAR DOME REPAIR 85 9.3.2 TIBIAL PLAFOND REPAIR 85 9.3.3 METATARSAL REPAIR 85 9.3.4 TALONAVICULAR JOINT REPAIR 85 9.3.5 SUBTALAR JOINT REPAIR 85 9.4 SOFT TISSUE TENDON & LIGAMENT REPAIR 85 9.4.1 TENDON AUGMENTATION 86 9.4.2 LIGAMENT REPAIR 86 9.4.3 FAT PAD REPLACEMENT 86 9.4.4 PLANTAR PLATE REPAIR 87 9.5 WOUND CARE 87 9.5.1 ANKLE ULCER TREATMENT 88 9.5.2 NEUROPATHIC FOOT ULCER TREATMENT 88 10 EUROPE FOOT AND ANKLE ALLOGRAFTS MARKET, BY PROCEDURE 89 10.1 OVERVIEW 90 10.2 MIDFOOT PROCEDURES 93 10.2.1 CUBOID FRACTURE 94 10.2.2 FIRST TARSOMETATARSAL JOINT ARTHRODESIS 94 10.2.3 MEDIAL COLUMN ARTHRODESIS 94 10.2.4 LISFRANC 94 10.2.5 MEDIAL CUNEIFORM DORSAL OPENING WEDGE (COTTON) OSTEOTOMY 94 10.2.6 NAVICULAR CUNEIFORM ARTHRODESIS 94 10.2.7 NAVICULAR FRACTURE 94 10.2.8 OTHER MIDFOOT PROCEDURES 94 10.3 HIND-FOOT PROCEDURES 94 10.3.1 CALCANEAL FRACTURE 95 10.3.2 LATERAL COLUMN LENGTHENING 95 10.3.3 TALONAVICULAR JOINT ARTHRODESIS 96 10.3.4 TRIPLE ARTHRODESIS 96 10.3.5 OTHER HINDFOOT PROCEDURES 96 11 EUROPE FOOT AND ANKLE ALLOGRAFTS MARKET, BY END USER 97 11.1 OVERVIEW 98 11.2 HOSPITALS 101 11.3 ORTHOPEDIC CLINICS 101 11.4 AMBULATORY SURGICAL CENTERS 102 11.5 ACADEMIC AND RESEARCH INSTITUTES 103 11.6 OTHER END USERS 104 12 EUROPE FOOT AND ANKLE ALLOGRAFT MARKET, BY REGION 105 12.1 EUROPE 106 12.1.1 U.K. 115 12.1.2 GERMANY 118 12.1.3 FRANCE 121 12.1.4 ITALY 124 12.1.5 SPAIN 127 12.1.6 RUSSIA 130 12.1.7 SWITZERLAND 133 12.1.8 NETHERLANDS 136 12.1.9 BELGIUM 139 12.1.10 TURKEY 142 12.1.11 REST OF EUROPE 145 13 EUROPE FOOT AND ANKLE ALLOGRAFTS MARKET: COMPANY LANDSCAPE 146 13.1 COMPANY SHARE ANALYSIS: EUROPE 146 14 SWOT ANALYSIS 147 15 COMPANY PROFILE 148 15.1 LIFENET HEALTH 148 15.1.1 COMPANY SNAPSHOT 148 15.1.2 COMPANY SHARE ANALYSIS 148 15.1.3 PRODUCT PORTFOLIO 149 15.1.4 RECENT DEVELOPMENTS 150 15.1.4.1 CONFERENCE 150 15.1.4.2 PRODUCT LAUNCH 151 15.2 ZIMMER BIOMET 152 15.2.1 COMPANY SNAPSHOT 152 15.2.2 REVENUE ANALYSIS 152 15.2.3 COMPANY SHARE ANALYSIS 153 15.2.4 PRODUCT PORTFOLIO 153 15.2.5 RECENT DEVELOPMENT 153 15.2.5.1 PARTNERSHIP 153 15.3 JOHNSON & JOHNSON SERVICES, INC. 154 15.3.1 COMPANY SNAPSHOT 154 15.3.2 REVENUE ANALYSIS 154 15.3.3 COMPANY SHARE ANALYSIS 155 15.3.4 PRODUCT PORTFOLIO 155 15.3.5 RECENT DEVELOPMENTS 155 15.3.5.1 EVENT 155 15.3.5.2 PRODUCT LAUNCH 155 15.4 INTEGRA LIFESCIENCES 156 15.4.1 COMPANY SNAPSHOT 156 15.4.2 REVENUE ANALYSIS 156 15.4.3 COMPANY SHARE ANALYSIS 157 15.4.4 PRODUCT PORTFOLIO 157 15.4.5 RECENT DEVELOPMENTS 157 15.4.5.1 POSITIVE CLINICAL OUTCOME 157 15.4.5.2 AGREEMENT 157 15.4.5.3 ACQUISITION 158 15.5 CONMED CORPORATION (2022) 159 15.5.1 COMPANY SNAPSHOT 159 15.5.2 REVENUE ANALYSIS 159 15.5.3 COMPANY SHARE ANALYSIS 160 15.5.4 PRODUCT PORTFOLIO 160 15.5.5 RECENT DEVELOPMENT 161 15.5.5.1 ACQUISITION 161 15.6 ALLOSOURCE 162 15.6.1 COMPANY SNAPSHOT 162 15.6.2 PRODUCT PORTFOLIO 162 15.6.3 RECENT DEVELOPMENT 163 15.6.3.1 PRODUCT LAUNCH 163 15.7 ALON SOURCE GROUP 164 15.7.1 COMPANY SNAPSHOT 164 15.7.2 PRODUCT PORTFOLIO 164 15.7.3 RECENT DEVELOPMENT 164 15.8 AMNIOX MEDICAL INC. 165 15.8.1 COMPANY SNAPSHOT 165 15.8.2 PRODUCT PORTFOLIO 165 15.8.3 RECENT DEVELOPMENT 165 15.8.3.1 PARTNERSHIP 165 15.9 ARTHREX 166 15.9.1 COMPANY SNAPSHOT 166 15.9.2 PRODUCT PORTFOLIO 166 15.9.3 RECENT DEVELOPMENT 166 15.9.3.1 PRODUCT LAUNCH 166 15.10 BIOVENTUS 167 15.10.1 COMPANY SNAPSHOT 167 15.10.2 REVENUE ANALYSIS 167 15.10.3 PRODUCT PORTFOLIO 168 15.10.4 RECENT DEVELOPMENT 168 15.10.4.1 CO-DEVELOPMENT 168 15.11 BONE BANK ALLOGRAFTS 169 15.11.1 COMPANY SNAPSHOT 169 15.11.2 PRODUCT PORTFOLIO 169 15.11.3 RECENT DEVELOPMENTS 169 15.11.3.1 PARTNERSHIP 169 15.12 GLOBUS MEDICAL 170 15.12.1 COMPANY SNAPSHOT 170 15.12.2 REVENUE ANALYSIS 170 15.12.3 PRODUCT PORTFOLIO 171 15.12.4 RECENT DEVELOPMENTS 171 15.12.4.1 M&A 171 15.13 INSTITUT STRAUMANN 172 15.13.1 COMPANY SNAPSHOT 172 15.13.2 REVENUE ANALYSIS 172 15.13.3 PRODUCT PORTFOLIO 173 15.13.4 RECENT DEVELOPMENT 173 15.14 JRF ORTHO 174 15.14.1 COMPANY SNAPSHOT 174 15.14.2 PRODUCT PORTFOLIO 174 15.14.3 RECENT DEVELOPMENT 175 15.14.3.1 PARTNERSHIP 175 15.15 NVISION BIOMEDICAL TECHNOLOGIES. 176 15.15.1 COMPANY SNAPSHOT 176 15.15.2 PRODUCT PORTFOLIO 176 15.15.3 RECENT DEVELOPMENT 176 15.15.3.1 ACQUISITION 176 15.16 PARAGON28, INC. 177 15.16.1 COMPANY SNAPSHOT 177 15.16.2 REVENUE ANALYSIS 177 15.16.3 PRODUCT PORTFOLIO 178 15.16.4 RECENT DEVELOPMENT 178 15.16.4.1 ACQUISITION 178 15.17 ORGANOGENESIS INC 179 15.17.1 COMPANY SNAPSHOT 179 15.17.2 REVENUE ANALYSIS 179 15.17.3 PRODUCT PORTFOLIO 180 15.17.4 RECENT DEVELOPMENTS 180 15.17.4.1 CONFERENCE 180 15.17.4.2 ACQUISITION 180 15.18 SMITH + NEPHEW 181 15.18.1 COMPANY SNAPSHOT 181 15.18.2 REVENUE ANALYSIS 181 15.18.3 PRODUCT PORTFOLIO 182 15.18.4 RECENT DEVELOPMENTS 182 15.18.4.1 EVENT 182 15.18.4.2 ACQUISITION 182 15.19 STRYKER 183 15.19.1 COMPANY SNAPSHOT 183 15.19.2 REVENUE ANALYSIS 183 15.19.3 PRODUCT PORTFOLIO 184 15.19.4 RECENT DEVELOPMENT 184 16 QUESTIONNAIRE 185 17 RELATED REPORTS 188